Benchmarking Disease Modifying Therapies for Alzheimer's Disease Using a Quantitative Systems Pharmacology Model
The link between Alzheimer’s disease (AD) pathological mechanisms and AD biomarkers was modeled to assess the potential impact of therapeutic interventions. A Quantitative Systems Pharmacology platform was used to model amyloid an tau pathologies between compartments (brain, cerebrospinal fluid, plasma) based on transport pathways. The model was created using observed and simulated data from four anti-amyloid antibodies (solanezumab, crenezumab, gantenerumab, aducanumab) and an anti-tau antibody (semorinemab).